Pliant Therapeutics releases longer-term safety, preliminary efficacy data from PhIIa study

A new update on Pliant Therapeutics’ oral drug for idiopathic pulmonary fibrosis (IPF) suggests its safety and early signs of efficacy are holding up in longer-term follow-up, setting the stage for a Phase IIb trial in the coming months. South San Francisco-based Pliant designed the Phase IIa INTEGRIS-IPF trial mainly…

...

Click to view original post